相关实验视频

Updated: Jun 17, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

miRNA-130a-3p/CPEB4轴调节质母细胞瘤的生长和进展

Hongchao Liu¹, Zhihao Wei¹, Kangke Shi¹

¹Department of Pathology, The Yiluo Hospital of Luoyang, The Teaching Hospital of Henan University of Science and Technology, Luoyang, China.

Technology in cancer research & treatment

|December 22, 2023

概括

微RNA-130a-3p (miR-130a-3p) 通过降低细胞质多基化元素结合蛋白4 (CPEB4) 的调节来抑制质母细胞瘤的生长. 这项研究揭示了一种针对质母细胞瘤中miR-130a-3p/CPEB4轴的新型治疗策略.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
生物化学生化学

背景情况:

质母细胞瘤是最常见的恶性脑瘤.
细胞质多基化元素结合蛋白4 (CPEB4) 过度表达,并促进质母细胞瘤瘤发生和转移.
微RNA-130a-3p (miR-130a-3p) 表达在瘤中发生变化,需要进行调查.

研究的目的:

研究miR-130a-3p在质母细胞瘤扩散和迁移中的作用和机制.
探索质母细胞瘤中miR-130a-3p和CPEB4之间的调节关系.

主要方法:

定量实时PCR检测miR-130a-3p和CPEB4的表达.
细胞活力 (MTT试验),迁移 (Transwell试验) 和细胞周期 (流细胞计) 分析.
对于CPEB4蛋白和上皮层-介质细胞过渡 (EMT) 标记物的西部涂抹.
生物信息学和 luciferase 记者测定证实了 miR-130a-3p 针对 CPEB4 的向.

主要成果:

在质母细胞瘤细胞系中,CPEB4是上调的,而miR-130a-3p是下调的.
miR-130a-3p直接准并降低CPEB4的表达.
增加的miR-130a-3p抑制了质母细胞细胞的增殖,迁移和EMT.
过度表达CPEB4可以抵消miR-130a-3p的抑制作用.

结论:

在质母细胞瘤中,miR-130a-3p的下调导致CPEB4的上调.
该miR-130a-3p/CPEB4轴显著影响质母细胞瘤的生长和迁移.
准miR-130a-3p/CPEB4通路为质母细胞瘤提供了一个潜在的治疗策略.

关键词:

在CPEB4EB4中使用.质母细胞瘤是一种质母细胞瘤.在 miR-130a-3p 中.移民移民迁移迁移它们的扩散和扩散.

更多相关视频

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...